首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1475197

全球慢性肾臟病 (CKD) 药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Chronic Kidney Disease (CKD) Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球慢性肾臟病 (CKD) 药物市场需求预计将从 2023 年的 150.6 亿美元达到近 236.9 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 5.16%。

慢性肾臟病 (CKD) 药物是用于治疗和管理长期肾臟损伤和功能障碍的药剂。他们的目标是减缓肾臟疾病的进展，控制症状，管理併发症，并降低与肾功能受损有关的心血管事件和死亡的风险。这些药物可能包括血管张力素转换酶 (ACE) 抑制剂、血管张力素 II 受体阻断剂 (ARB)、利尿剂、红血球生成刺激剂 (ESA)、磷酸盐结合剂和维生素 D 类似物等。

市场动态

糖尿病、高血压、肥胖和人口老化等危险因子的持续发生，推动了 CKD 的盛行率，导致越来越多的患者群体需要药物干预来减缓疾病进展、控制症状和提高生活品质。随着人们对CKD 认识的不断提高、早期检测倡议以及推动识别高风险个体和无症状病例的筛检计划的实施等因素，对具有肾臟保护作用、降低心血管风险和预防疾病的CKD 药物的需求不断增长。

此外，随着製药公司、生物技术新创公司和学术研究人员投资于针对 CKD 併发症的药物发现和开发项目，人们越来越认识到 CKD 作为全球公共卫生挑战，推动了市场创新。此外，随着製造商探索监管途径、展示临床疗效并获得市场批准，不断变化的监管环境、临床试验设计和报销政策推动了 CKD 药物的市场竞争、定价动态和市场准入。然而，对药物安全性、有效性和不良反应的担忧可能会挑战未来几年慢性肾臟病 (CKD) 药物市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球慢性肾臟病 (ckd) 药物市场的各个细分市场进行了包容性评估。慢性肾臟病 (ckd) 药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

慢性肾臟病 (CKD) 药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按药物类别

ACE抑制剂
血管张力素-II 受体阻断剂
钙通道阻断剂
β受体阻断剂
红血球生成刺激剂 (Esas)
利尿剂
其他的

按最终用户

医院
专科诊所

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的慢性肾臟病 (CKD) 药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。慢性肾臟病（CKD）药物市场的主要参与者包括罗氏有限公司、辉瑞公司、赛诺菲公司、葛兰素史克公司、Kissei Pharmaceutical Co. Ltd.、艾伯维公司、Akebia Therapeutics Inc.、阿斯特捷利康公司、安进公司(Amgen Inc.)、梯瓦製药工业有限公司(Teva Pharmaceutical Industries Ltd.)。、财务概览、合作、新产品开发、新产品发布、以及其他进度。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：慢性肾臟病 (CKD) 药品公司的竞争格局

慢性肾臟病（CKD）药物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
F. Hoffmann-La Roche Ltd.

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Sanofi

公司简介
公司收入
产品
最近的发展

GSK Plc

公司简介
公司收入
产品
最近的发展

Kissei Pharmaceutical Co. Ltd.

公司简介
公司收入
产品
最近的发展

AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Akebia Therapeutics Inc.

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

Amgen Inc.

公司简介
公司收入
产品
最近的发展

Teva Pharmaceutical Industries Ltd.

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114354

The global demand for Chronic Kidney Disease (CKD) Drugs Market is presumed to reach the market size of nearly USD 23.69 Billion by 2032 from USD 15.06 Billion in 2023 with a CAGR of 5.16% under the study period 2024 - 2032.

Chronic kidney disease (CKD) drugs are pharmaceutical agents used to treat and manage long-term kidney damage and dysfunction. They aim to slow the progression of kidney disease, control symptoms, manage complications, and reduce the risk of cardiovascular events and mortality concerned with impaired kidney function. These drugs may include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, erythropoiesis-stimulating agents (ESAs), phosphate binders, and vitamin D analogs, among others.

MARKET DYNAMICS

The spurring incidence of risk factors such as diabetes, hypertension, obesity, and aging populations drives the prevalence of CKD, leading to a growing patient population in need of pharmacological interventions to slow disease progression, manage symptoms, and enhance quality of life. With factors such as the increasing awareness of CKD, early detection initiatives, and the implementation of screening programs driving the identification of high-risk individuals and asymptomatic cases, there is a growing demand for CKD drugs that offer renoprotective effects, cardiovascular risk reduction, and symptom relief in patients with CKD stages 1 to 5. Additionally, advancements in renal biology, pathophysiology, and biomarker research enable the identification of novel drug targets, mechanisms of action, and therapeutic strategies for CKD treatment and management.

Moreover, the increasing recognition of CKD as a global public health challenge drives market innovation as pharmaceutical companies, biotech startups, and academic researchers invest in drug discovery and development programs targeting CKD complications. Furthermore, the evolving regulatory landscape, clinical trial design, and reimbursement policies drive market competition, pricing dynamics, and market access for CKD drugs as manufacturers navigate regulatory pathways, demonstrate clinical efficacy, and secure market approvals. However, concerns over drug safety, effectiveness, and adverse effects may challenge the chronic kidney disease (CKD) drugs market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of chronic kidney disease (ckd) drugs. The growth and trends of chronic kidney disease (ckd) drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the chronic kidney disease (ckd) drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

ACE Inhibitors
Angiotensin-Ii Receptor Blockers
Calcium Channel Blockers
Beta Blockers
Erythropoiesis-Stimulating Agents (Esas)
Diuretics
Others

By End-User

Hospitals
Specialty Clinics

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Chronic Kidney Disease (CKD) Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Chronic Kidney Disease (CKD) Drugs market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GSK plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Akebia Therapeutics Inc., AstraZeneca, Amgen Inc., Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CHRONIC KIDNEY DISEASE (CKD) DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By End-user
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. ACE Inhibitors Historic and Forecast Sales By Regions
5.5. Angiotensin-II Receptor Blockers Historic and Forecast Sales By Regions
5.6. Calcium Channel Blockers Historic and Forecast Sales By Regions
5.7. Beta Blockers Historic and Forecast Sales By Regions
5.8. Erythropoiesis-stimulating Agents (ESAs) Historic and Forecast Sales By Regions
5.9. Diuretics Historic and Forecast Sales By Regions
5.10. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY END-USER

6.1. Overview By End-user
6.2. Historical and Forecast Data
6.3. Analysis By End-user
6.4. Hospitals Historic and Forecast Sales By Regions
6.5. Specialty Clinics Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CHRONIC KIDNEY DISEASE (CKD) DRUGS COMPANIES

8.1. Chronic Kidney Disease (CKD) Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF CHRONIC KIDNEY DISEASE (CKD) DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Pfizer Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Sanofi
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. GSK Plc
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Kissei Pharmaceutical Co. Ltd.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. AbbVie Inc.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Akebia Therapeutics Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. AstraZeneca
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Amgen Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Teva Pharmaceutical Industries Ltd.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments